CLASSICAL HODGKIN LYMPHOMA
Clinical trials for CLASSICAL HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new CLASSICAL HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for CLASSICAL HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cancer drug combo tested in early trial
Disease control TerminatedThis early-phase study tested a new drug, PF-08046032, alone or with another drug (sasanlimab) in 6 adults with advanced lymphomas or solid tumors that had spread. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated May 17, 2026 06:52 UTC
-
Promising lymphoma drug trial halted early after enrolling only 3 patients
Disease control TerminatedThis study tested a drug called tislelizumab against standard chemotherapy for people with classical Hodgkin lymphoma that returned or didn't respond to prior treatments. Only 3 people took part before the study was stopped early. The goal was to see if tislelizumab could delay c…
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE3 • Sponsor: BeiGene • Aim: Disease control
Last updated May 17, 2026 06:46 UTC
-
Early trial of GEN3017 for Hard-to-Treat lymphomas ends early
Disease control TerminatedThis early-stage trial tested a new drug called GEN3017 in 9 people with CD30-positive Hodgkin or Non-Hodgkin lymphoma that had returned or stopped responding to other treatments. The goal was to check the drug's safety and how well the body tolerates it. The study was terminated…
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated May 11, 2026 20:52 UTC